276 related articles for article (PubMed ID: 30791119)
21. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi.
Papp T; Schipper H; Kumar K; Schiffmann D; Zimmermann R
Melanoma Res; 2005 Oct; 15(5):401-7. PubMed ID: 16179867
[TBL] [Abstract][Full Text] [Related]
22. Detection of cell-free circulating BRAF
Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
[TBL] [Abstract][Full Text] [Related]
23. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
24. Biology and genetics of acquired and congenital melanocytic naevi.
Maher NG; Scolyer RA; Colebatch AJ
Pathology; 2023 Mar; 55(2):169-177. PubMed ID: 36635156
[TBL] [Abstract][Full Text] [Related]
25. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
26. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
Thomas NE
Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
[TBL] [Abstract][Full Text] [Related]
27.
Bansal N; Das M; Chatterjee U; Mallick MG; Arora N; Mishra DK
Indian J Pathol Microbiol; 2021; 64(2):402-405. PubMed ID: 33851646
[TBL] [Abstract][Full Text] [Related]
28. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
29. Malignant melanoma arising from an NRAS-mutated medium-sized congenital melanocytic nevus.
Kiyohara T; Takata M; Itoh H; Kawami K; Ido H; Ishida H; Kumakiri M
J Dermatol; 2012 Dec; 39(12):1034-5. PubMed ID: 22452623
[No Abstract] [Full Text] [Related]
30. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
[TBL] [Abstract][Full Text] [Related]
31. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
Uribe P; Wistuba II; González S
Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
[TBL] [Abstract][Full Text] [Related]
32. Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi.
Polubothu S; McGuire N; Al-Olabi L; Baird W; Bulstrode N; Chalker J; Josifova D; Lomas D; O'Hara J; Ong J; Rampling D; Stadnik P; Thomas A; Wedgeworth E; Sebire NJ; Kinsler VA
Br J Dermatol; 2020 Feb; 182(2):434-443. PubMed ID: 31111470
[TBL] [Abstract][Full Text] [Related]
33. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
34. Congenital melanocytic nevi: update in genetics and management.
Price HN
Curr Opin Pediatr; 2016 Aug; 28(4):476-82. PubMed ID: 27307047
[TBL] [Abstract][Full Text] [Related]
35. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
[TBL] [Abstract][Full Text] [Related]
36. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
37. High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients.
Masaki T; Wang Y; DiGiovanna JJ; Khan SG; Raffeld M; Beltaifa S; Hornyak TJ; Darling TN; Lee CC; Kraemer KH
Pigment Cell Melanoma Res; 2014 May; 27(3):454-64. PubMed ID: 24483290
[TBL] [Abstract][Full Text] [Related]
38. Dysplastic/Clark naevus in the era of molecular pathology.
Mesbah Ardakani N
Australas J Dermatol; 2019 Aug; 60(3):186-191. PubMed ID: 30854639
[TBL] [Abstract][Full Text] [Related]
39. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
40. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]